FDA Approves Repeat Treatment Labeling for Glaukos’ iDose TR in Glaucoma

Glaukos gets FDA nod for iDose TR re-administration

The iDose TR device. [Image from Glaukos]Glaukos (NYSE:GKOS) announced today that the FDA approved a new drug application (NDA) labeling supplement for its iDose TR system. iDose TR (travoprost intracameral implant) offers the reduction of intraocular pressure (IOP). It treats patients with ocular hypertension (OHT) or open-angle glaucoma (OAG). The first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy. It continuously…

FDA Approves Repeat Treatment Labeling for Glaukos’ iDose TR in Glaucoma

Glaukos announced that the FDA has approved a new drug application (NDA) labeling supplement for iDose TR that allows for re-administration using a repeat treatment protocol. The FDA approval follows Glaukos’ 2025 NDA labeling supplement submission and is supported by accumulated clinical evidence demonstrating the safety and tolerability of repeat use of iDose TR. According to Glaukos, the updated labeling provides physicians with additional fl…